APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Hirudin

This report studies the Hirudin market. Hirudin is a naturally occurring peptide in the salivary glands of medicinal leeches (such as Hirudo medicinalis) that has a blood anticoagulant property. Hirudin is the most potent natural inhibitor of thrombin. Hirudin (hirudin) is a Leech (Leech) and salivary glands have been extracted from a variety of active ingredients in the activity of the most significant and most studied ingredients, which is 65-66 amino acids from the small molecules of protein (peptide) . Hirudin have strong inhibitory effect on thrombin is the strongest so far found in the natural specific inhibitor of thrombin. Animal experiments and clinical studies have shown that hirudin can be effective anticoagulant, antithrombotic, and prevent thrombin-catalyzed activation of coagulation factors and platelet reactions and blood stasis phenomenon further. In addition, it also inhibited thrombin-induced fibroblast proliferation, and thrombin stimulation of endothelial cells. Compared with heparin, which not only use less, do not cause bleeding, is not dependent on endogenous cofactor; and heparin have caused the risk of bleeding, disseminated intravascular coagulation in the pathogenesis of antithrombin III are reduced This will limit the efficacy of heparin, using leeches will have good results.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

This report studies the Hirudin market. Hirudin is a naturally occurring peptide in the salivary glands of medicinal leeches (such as Hirudo medicinalis) that has a blood anticoagulant property. Hirudin is the most potent natural inhibitor of thrombin. Hirudin (hirudin) is a Leech (Leech) and salivary glands have been extracted from a variety of active ingredients in the activity of the most significant and most studied ingredients, which is 65-66 amino acids from the small molecules of protein (peptide) . Hirudin have strong inhibitory effect on thrombin is the strongest so far found in the natural specific inhibitor of thrombin. Animal experiments and clinical studies have shown that hirudin can be effective anticoagulant, antithrombotic, and prevent thrombin-catalyzed activation of coagulation factors and platelet reactions and blood stasis phenomenon further. In addition, it also inhibited thrombin-induced fibroblast proliferation, and thrombin stimulation of endothelial cells. Compared with heparin, which not only use less, do not cause bleeding, is not dependent on endogenous cofactor; and heparin have caused the risk of bleeding, disseminated intravascular coagulation in the pathogenesis of antithrombin III are reduced This will limit the efficacy of heparin, using leeches will have good results.

Selected research

Market Outlook & Growth Opportunities

Global Hirudin Market Outlook and Growth Opportunities 2026

Report ID 17328735041 January 2026191 pages

Choose your research edition.

Industry ResearchHirudin Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Hirudin Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Hirudin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hirudin Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Hirudin Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

This report studies the Hirudin market. Hirudin is a naturally occurring peptide in the salivary glands of medicinal leeches (such as Hirudo medicinalis) that has a blood anticoagulant property. Hirudin is the most potent natural inhibitor of thrombin. Hirudin (hirudin) is a Leech (Leech) and salivary glands have been extracted from a variety of active ingredients in the activity of the most significant and most studied ingredients, which is 65-66 amino acids from the small molecules of protein (peptide) . Hirudin have strong inhibitory effect on thrombin is the strongest so far found in the natural specific inhibitor of thrombin. Animal experiments and clinical studies have shown that hirudin can be effective anticoagulant, antithrombotic, and prevent thrombin-catalyzed activation of coagulation factors and platelet reactions and blood stasis phenomenon further. In addition, it also inhibited thrombin-induced fibroblast proliferation, and thrombin stimulation of endothelial cells. Compared with heparin, which not only use less, do not cause bleeding, is not dependent on endogenous cofactor; and heparin have caused the risk of bleeding, disseminated intravascular coagulation in the pathogenesis of antithrombin III are reduced This will limit the efficacy of heparin, using leeches will have good results.

Global Hirudin key players include Pfizer, Teva Pharmaceutical, The Medicines Company, SALUBRIS, DUOPUTAI, etc. Global top five manufacturers hold a share about 20%. North America is the largest market, with a share about 30%, followed by Europe, with a share about 20 percent. In terms of product, Natural Hirudin is the largest segment, with a share about 55%. And in terms of application, the largest application is Thrombosis Disease, followed by Tumor Disease, etc.

This report provides an overview of the global Hirudin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Hirudin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hirudin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hirudin market size, projected growth trends, production technologies, key applications, and end-use industries.

Hirudin Segment by Company

The Medicines Company

Keyken

Minapharm

Abbott

SALUBRIS

Pfizer, Inc

Teva Pharmaceutical Industries Ltd

DUOPUTAI

Pentapharm

Hirudin Segment by Type

Natural Hirudin

Recombinant Hirudin

Hirudin Segment by Application

Thrombosis Disease

Tumor Disease

Others

Hirudin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Hirudin status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Hirudin market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hirudin significant trends, drivers, influence factors in global and regions.

6. To analyze Hirudin competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hirudin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hirudin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hirudin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Hirudin market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hirudin industry.

Chapter 3: Detailed analysis of Hirudin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Hirudin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Hirudin in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hirudin Industry Trends Table 2. Hirudin Industry Drivers Table 3. Hirudin Industry Opportunities and Challenges Table 4. Hirudin Industry Restraints Table 5. Global Hirudin Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hirudin Revenue Share by Company (2021-2026) Table 7. Global Hirudin Sales Volume by Company (MT) & (2021-2026) Table 8. Global Hirudin Sales Volume Share by Company (2021-2026) Table 9. Global Hirudin Average Price (USD/Kg) of Company (2021-2026) Table 10. Global Hirudin Company Ranking, (2024-2026) & (USD Million) Table 11. Global Hirudin Key Company Manufacturing Base & Headquarters Table 12. Global Hirudin Company, Product Type & Application Table 13. Global Hirudin Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Hirudin by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Natural Hirudin Table 18. Significant Companies of Recombinant Hirudin Table 19. Global Hirudin Sales Volume by Type 2021 VS 2025 VS 2032 (MT) Table 20. Global Hirudin Sales Volume by Type (2021-2026) & (MT) Table 21. Global Hirudin Sales Volume by Type (2027-2032) & (MT) Table 22. Global Hirudin Sales Volume Share by Type (2021-2026) Table 23. Global Hirudin Sales Volume Share by Type (2027-2032) Table 24. Global Hirudin Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Hirudin Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Hirudin Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Hirudin Sales Value Share by Type (2021-2026) Table 28. Global Hirudin Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Thrombosis Disease Table 30. Significant Companies of Tumor Disease Table 31. Significant Companies of Others Table 32. Global Hirudin Sales Volume by Application 2021 VS 2025 VS 2032 (MT) Table 33. Global Hirudin Sales Volume by Application (2021-2026) & (MT) Table 34. Global Hirudin Sales Volume by Application (2027-2032) & (MT) Table 35. Global Hirudin Sales Volume Share by Application (2021-2026) Table 36. Global Hirudin Sales Volume Share by Application (2027-2032) Table 37. Global Hirudin Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Hirudin Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Hirudin Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Hirudin Sales Value Share by Application (2021-2026) Table 41. Global Hirudin Sales Value Share by Application (2027-2032) Table 42. Global Hirudin Sales by Region: 2021 VS 2025 VS 2032 (MT) Table 43. Global Hirudin Sales by Region (2021-2026) & (MT) Table 44. Global Hirudin Sales Market Share by Region (2021-2026) Table 45. Global Hirudin Sales by Region (2027-2032) & (MT) Table 46. Global Hirudin Sales Market Share by Region (2027-2032) Table 47. Global Hirudin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Hirudin Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Hirudin Sales Value Share by Region (2021-2026) Table 50. Global Hirudin Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Hirudin Sales Value Share by Region (2027-2032) Table 52. Global Hirudin Market Average Price (USD/Kg) by Region (2021-2026) Table 53. Global Hirudin Market Average Price (USD/Kg) by Region (2027-2032) Table 54. Global Hirudin Sales by Country: 2021 VS 2025 VS 2032 (MT) Table 55. Global Hirudin Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Hirudin Sales by Country (2021-2026) & (MT) Table 57. Global Hirudin Sales Market Share by Country (2021-2026) Table 58. Global Hirudin Sales by Country (2027-2032) & (MT) Table 59. Global Hirudin Sales Market Share by Country (2027-2032) Table 60. Global Hirudin Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Hirudin Sales Value Market Share by Country (2021-2026) Table 62. Global Hirudin Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Hirudin Sales Value Market Share by Country (2027-2032) Table 64. The Medicines Company Company Information Table 65. The Medicines Company Business Overview Table 66. The Medicines Company Hirudin Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2021-2026) Table 67. The Medicines Company Hirudin Product Portfolio Table 68. The Medicines Company Recent Development Table 69. Keyken Company Information Table 70. Keyken Business Overview Table 71. Keyken Hirudin Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2021-2026) Table 72. Keyken Hirudin Product Portfolio Table 73. Keyken Recent Development Table 74. Minapharm Company Information Table 75. Minapharm Business Overview Table 76. Minapharm Hirudin Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2021-2026) Table 77. Minapharm Hirudin Product Portfolio Table 78. Minapharm Recent Development Table 79. Abbott Company Information Table 80. Abbott Business Overview Table 81. Abbott Hirudin Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2021-2026) Table 82. Abbott Hirudin Product Portfolio Table 83. Abbott Recent Development Table 84. SALUBRIS Company Information Table 85. SALUBRIS Business Overview Table 86. SALUBRIS Hirudin Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2021-2026) Table 87. SALUBRIS Hirudin Product Portfolio Table 88. SALUBRIS Recent Development Table 89. Pfizer, Inc Company Information Table 90. Pfizer, Inc Business Overview Table 91. Pfizer, Inc Hirudin Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2021-2026) Table 92. Pfizer, Inc Hirudin Product Portfolio Table 93. Pfizer, Inc Recent Development Table 94. Teva Pharmaceutical Industries Ltd Company Information Table 95. Teva Pharmaceutical Industries Ltd Business Overview Table 96. Teva Pharmaceutical Industries Ltd Hirudin Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2021-2026) Table 97. Teva Pharmaceutical Industries Ltd Hirudin Product Portfolio Table 98. Teva Pharmaceutical Industries Ltd Recent Development Table 99. DUOPUTAI Company Information Table 100. DUOPUTAI Business Overview Table 101. DUOPUTAI Hirudin Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2021-2026) Table 102. DUOPUTAI Hirudin Product Portfolio Table 103. DUOPUTAI Recent Development Table 104. Pentapharm Company Information Table 105. Pentapharm Business Overview Table 106. Pentapharm Hirudin Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2021-2026) Table 107. Pentapharm Hirudin Product Portfolio Table 108. Pentapharm Recent Development Table 109. Key Raw Materials Table 110. Raw Materials Key Suppliers Table 111. Hirudin Distributors List Table 112. Hirudin Customers List Table 113. Research Programs/Design for This Report Table 114. Authors List of This Report Table 115. Secondary Sources Table 116. Primary Sources List of Figures Figure 1. Hirudin Product Image Figure 2. Global Hirudin Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hirudin Sales Value (2021-2032) & (US$ Million) Figure 4. Global Hirudin Sales (2021-2032) & (MT) Figure 5. Global Hirudin Sales Average Price (USD/Kg) & (2021-2032) Figure 6. Global Hirudin Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Natural Hirudin Image Figure 10. Recombinant Hirudin Image Figure 11. Global Hirudin Sales Volume by Type (2021 VS 2025 VS 2032) & (MT) Figure 12. Global Hirudin Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Hirudin Sales Volume Share by Type (2021-2032) Figure 14. Global Hirudin Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Hirudin Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Hirudin Sales Value Share by Type (2021-2032) Figure 17. Thrombosis Disease Image Figure 18. Tumor Disease Image Figure 19. Others Image Figure 20. Global Hirudin Sales Volume by Application (2021 VS 2025 VS 2032) & (MT) Figure 21. Global Hirudin Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Hirudin Sales Volume Share by Application (2021-2032) Figure 23. Global Hirudin Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Hirudin Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Hirudin Sales Value Share by Application (2021-2032) Figure 26. Global Hirudin Sales by Region: 2021 VS 2025 VS 2032 (MT) Figure 27. Global Hirudin Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Hirudin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Hirudin Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Hirudin Sales Value (2021-2032) & (US$ Million) Figure 31. North America Hirudin Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Hirudin Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Hirudin Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Hirudin Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Hirudin Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Hirudin Sales Value (2021-2032) & (US$ Million) Figure 37. South America Hirudin Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Hirudin Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Hirudin Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Hirudin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Hirudin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Hirudin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Hirudin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Hirudin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Hirudin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Hirudin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Hirudin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Hirudin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Hirudin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Hirudin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Hirudin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Hirudin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Hirudin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Hirudin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Hirudin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Hirudin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Hirudin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Hirudin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Hirudin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Hirudin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Hirudin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Hirudin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Hirudin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Hirudin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Hirudin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Hirudin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Hirudin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Hirudin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Hirudin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Hirudin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Hirudin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Hirudin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Hirudin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Hirudin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Hirudin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Hirudin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Hirudin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Hirudin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Hirudin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Hirudin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Hirudin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Hirudin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Hirudin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Hirudin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Hirudin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Hirudin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Hirudin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Hirudin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Hirudin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Hirudin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Hirudin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Hirudin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Hirudin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Hirudin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Hirudin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Hirudin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Hirudin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Hirudin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Hirudin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Hirudin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Hirudin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Hirudin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Hirudin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Hirudin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Hirudin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Hirudin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Hirudin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Hirudin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Hirudin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Hirudin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Hirudin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Hirudin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Hirudin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Hirudin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Hirudin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Hirudin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Hirudin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Hirudin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Hirudin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Hirudin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Hirudin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Hirudin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Hirudin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Hirudin Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Hirudin Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Natural Hirudin
  • Recombinant Hirudin
Applications
  • Thrombosis Disease
  • Tumor Disease
  • Others
Companies covered
  • The Medicines Company
  • Keyken
  • Minapharm
  • Abbott
  • SALUBRIS
  • Pfizer, Inc
  • Teva Pharmaceutical Industries Ltd
  • DUOPUTAI
  • Pentapharm

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Hirudin Sales Value (2021-2032)
  4. 1.2.2 Global Hirudin Sales Volume (2021-2032)
  5. 1.2.3 Global Hirudin Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Hirudin Market Dynamics
  1. 2.1 Hirudin Industry Trends
  2. 2.2 Hirudin Industry Drivers
  3. 2.3 Hirudin Industry Opportunities and Challenges
  4. 2.4 Hirudin Industry Restraints
3 Hirudin Market by Company
  1. 3.1 Global Hirudin Company Revenue Ranking in 2025
  2. 3.2 Global Hirudin Revenue by Company (2021-2026)
  3. 3.3 Global Hirudin Sales Volume by Company (2021-2026)
  4. 3.4 Global Hirudin Average Price by Company (2021-2026)
  5. 3.5 Global Hirudin Company Ranking (2024-2026)
  6. 3.6 Global Hirudin Company Manufacturing Base and Headquarters
  7. 3.7 Global Hirudin Company Product Type and Application
  8. 3.8 Global Hirudin Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Hirudin Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Hirudin Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Hirudin Market by Type
  1. 4.1 Hirudin Type Introduction
  2. 4.1.1 Natural Hirudin
  3. 4.1.2 Recombinant Hirudin
  4. 4.2 Global Hirudin Sales Volume by Type
  5. 4.2.1 Global Hirudin Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Hirudin Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Hirudin Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Hirudin Sales Value by Type
  9. 4.3.1 Global Hirudin Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Hirudin Sales Value by Type (2021-2032)
  11. 4.3.3 Global Hirudin Sales Value Share by Type (2021-2032)
5 Hirudin Market by Application
  1. 5.1 Hirudin Application Introduction
  2. 5.1.1 Thrombosis Disease
  3. 5.1.2 Tumor Disease
  4. 5.1.3 Others
  5. 5.2 Global Hirudin Sales Volume by Application
  6. 5.2.1 Global Hirudin Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hirudin Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Hirudin Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Hirudin Sales Value by Application
  10. 5.3.1 Global Hirudin Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Hirudin Sales Value by Application (2021-2032)
  12. 5.3.3 Global Hirudin Sales Value Share by Application (2021-2032)
6 Hirudin Regional Sales and Value Analysis
  1. 6.1 Global Hirudin Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hirudin Sales by Region (2021-2032)
  3. 6.2.1 Global Hirudin Sales by Region: 2021-2026
  4. 6.2.2 Global Hirudin Sales by Region (2027-2032)
  5. 6.3 Global Hirudin Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Hirudin Sales Value by Region (2021-2032)
  7. 6.4.1 Global Hirudin Sales Value by Region: 2021-2026
  8. 6.4.2 Global Hirudin Sales Value by Region (2027-2032)
  9. 6.5 Global Hirudin Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Hirudin Sales Value (2021-2032)
  12. 6.6.2 North America Hirudin Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Hirudin Sales Value (2021-2032)
  15. 6.7.2 Europe Hirudin Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Hirudin Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Hirudin Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Hirudin Sales Value (2021-2032)
  21. 6.9.2 South America Hirudin Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Hirudin Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Hirudin Sales Value Share by Country, 2025 VS 2032
7 Hirudin Country-level Sales and Value Analysis
  1. 7.1 Global Hirudin Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hirudin Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Hirudin Sales by Country (2021-2032)
  4. 7.3.1 Global Hirudin Sales by Country (2021-2026)
  5. 7.3.2 Global Hirudin Sales by Country (2027-2032)
  6. 7.4 Global Hirudin Sales Value by Country (2021-2032)
  7. 7.4.1 Global Hirudin Sales Value by Country (2021-2026)
  8. 7.4.2 Global Hirudin Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Hirudin Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Hirudin Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Hirudin Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Hirudin Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Hirudin Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Hirudin Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Hirudin Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Hirudin Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Hirudin Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Hirudin Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Hirudin Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Hirudin Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Hirudin Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Hirudin Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Hirudin Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Hirudin Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Hirudin Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Hirudin Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Hirudin Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Hirudin Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Hirudin Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Hirudin Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Hirudin Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Hirudin Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Hirudin Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Hirudin Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Hirudin Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Hirudin Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Hirudin Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Hirudin Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Hirudin Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Hirudin Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Hirudin Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Hirudin Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Hirudin Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Hirudin Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Hirudin Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Hirudin Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Hirudin Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Hirudin Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Hirudin Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Hirudin Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Hirudin Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Hirudin Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Hirudin Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Hirudin Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Hirudin Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Hirudin Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Hirudin Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Hirudin Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Hirudin Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Hirudin Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Hirudin Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Hirudin Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Hirudin Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Hirudin Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Hirudin Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Hirudin Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Hirudin Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Hirudin Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Hirudin Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Hirudin Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Hirudin Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Hirudin Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Hirudin Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Hirudin Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Hirudin Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Hirudin Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Hirudin Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Hirudin Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Hirudin Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Hirudin Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Hirudin Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Hirudin Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Hirudin Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Hirudin Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Hirudin Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Hirudin Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Hirudin Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Hirudin Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Hirudin Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Hirudin Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Hirudin Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Hirudin Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 The Medicines Company
  2. 8.1.1 The Medicines Company Company Information
  3. 8.1.2 The Medicines Company Business Overview
  4. 8.1.3 The Medicines Company Hirudin Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 The Medicines Company Hirudin Product Portfolio
  6. 8.1.5 The Medicines Company Recent Developments
  7. 8.2 Keyken
  8. 8.2.1 Keyken Company Information
  9. 8.2.2 Keyken Business Overview
  10. 8.2.3 Keyken Hirudin Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Keyken Hirudin Product Portfolio
  12. 8.2.5 Keyken Recent Developments
  13. 8.3 Minapharm
  14. 8.3.1 Minapharm Company Information
  15. 8.3.2 Minapharm Business Overview
  16. 8.3.3 Minapharm Hirudin Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Minapharm Hirudin Product Portfolio
  18. 8.3.5 Minapharm Recent Developments
  19. 8.4 Abbott
  20. 8.4.1 Abbott Company Information
  21. 8.4.2 Abbott Business Overview
  22. 8.4.3 Abbott Hirudin Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Abbott Hirudin Product Portfolio
  24. 8.4.5 Abbott Recent Developments
  25. 8.5 SALUBRIS
  26. 8.5.1 SALUBRIS Company Information
  27. 8.5.2 SALUBRIS Business Overview
  28. 8.5.3 SALUBRIS Hirudin Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 SALUBRIS Hirudin Product Portfolio
  30. 8.5.5 SALUBRIS Recent Developments
  31. 8.6 Pfizer, Inc
  32. 8.6.1 Pfizer, Inc Company Information
  33. 8.6.2 Pfizer, Inc Business Overview
  34. 8.6.3 Pfizer, Inc Hirudin Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer, Inc Hirudin Product Portfolio
  36. 8.6.5 Pfizer, Inc Recent Developments
  37. 8.7 Teva Pharmaceutical Industries Ltd
  38. 8.7.1 Teva Pharmaceutical Industries Ltd Company Information
  39. 8.7.2 Teva Pharmaceutical Industries Ltd Business Overview
  40. 8.7.3 Teva Pharmaceutical Industries Ltd Hirudin Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Teva Pharmaceutical Industries Ltd Hirudin Product Portfolio
  42. 8.7.5 Teva Pharmaceutical Industries Ltd Recent Developments
  43. 8.8 DUOPUTAI
  44. 8.8.1 DUOPUTAI Company Information
  45. 8.8.2 DUOPUTAI Business Overview
  46. 8.8.3 DUOPUTAI Hirudin Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 DUOPUTAI Hirudin Product Portfolio
  48. 8.8.5 DUOPUTAI Recent Developments
  49. 8.9 Pentapharm
  50. 8.9.1 Pentapharm Company Information
  51. 8.9.2 Pentapharm Business Overview
  52. 8.9.3 Pentapharm Hirudin Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Pentapharm Hirudin Product Portfolio
  54. 8.9.5 Pentapharm Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Hirudin Value Chain Analysis
  2. 9.1.1 Hirudin Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Hirudin Sales Mode & Process
  6. 9.2 Hirudin Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Hirudin Distributors
  9. 9.2.3 Hirudin Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst